Cationic liposomes have been successfully used as an alternative approach to viral systems to deliver nucleic acids. However, high toxicity and inconsistent transfection efficiency have been associated with the currently available liposomes. Therefore, a novel cationic liposome was developed based on a synthetic cationic cardiolipin analogue (CCLA) to test the DNA transfection efficiency. This CCLA-based liposome was also used to determine the therapeutic efficacy of c-raf small interfering RNA (siRNA) in mice. In this report, we showed that the CCLA-based liposome was less toxic and effectively transfected reporter genes in vitro and in vivo. The transfection efficiency in mice was seven-fold higher than the commercially available DOTAP-based liposome. In addition, craf siRNA in the presence of CCLA-based liposome induced up to 62% of growth inhibition in cancer cells. Treatment of c-raf siRNA/CCLA complex in SCID mice bearing human breast xenograft tumors resulted in 73% of tumor growth suppression as compared to free c-raf siRNA group. In conclusion, a novel CCLA-based liposome showed less toxicity and broad usage both in vitro and in vivo with DNA and siRNA.
T he use of positively charged lipids in transfection reagents was first demonstrated in 1987 by Felgner et al. 1 Since then, many cationic liposome-based transfection reagents have been documented. 2, 3 Cationic lipids have been shown to actively enhance the delivery of plasmids 4 and the expression of the transfected genes can be detected in lungs as early as 60 minutes after intravenous (i.v.) administration. 5 The positive charge significantly increases the uptake of the liposomes by the endothelial cells of the blood vessels in tumor tissues 6 and this has made the cationic liposomes useful for tumor targeted drug delivery. Although cationic liposomes have been used to transfect nucleic acids in cells for several years, their application in gene therapy is limited because of the variable transfection 7, 8 and systemic toxicity when injected i.v. [9] [10] [11] To circumvent the problems associated with systemic administration, cationic liposomes have been made to deliver genes locally. [12] [13] [14] Recognizing the need for the development of new cationic lipids to improve gene therapy and drug delivery, we had successfully synthesized new cationic lipids based on the structure of cardiolipin. Cardiolipin (glycerolbridged dimeric phosphatidic acid, Fig 1a) is a class of phospholipids mainly present in the heart and skeletal muscles with high metabolic activity. 15 Among current existing cationic lipids, it has been reported that an ether linkage containing cationic lipid, such as 1,2-dioleyloxypropyl-3-trimethylammonium chloride (DOTMA), has greater in vivo transfection efficiency than the corresponding ester analogue 1,2,-dioleoyl-3-trimethylammoniumpropane (DOTAP). 16 In addition, a dimeric structure based on glycerol moiety with a longer alkyl chain has also been shown to enhance the lipid interaction with the cell membrane and therefore improve the gene transfection. 17 All the evidences had prompted us to synthesize ether-linked cardiolipin analogue where the phosphate groups of cardiolipin were replaced with quaternary ammonium groups (Fig 1b and Kasireddy et al 18 ). This synthetic cationic cardiolipin analogue (CCLA) was used to develop cationic liposome for in vitro and in vivo transfection.
Among different nucleic acid therapies, use of small interfering RNA (siRNA) has gained importance because of its specificity and potency against the target genes. 19 Although several therapeutic applications of siRNA have been proposed including viral infection and cancer, delivery of siRNA in vivo remains as a challenge due to its rapid degradation. 20 In the current study, we have investigated the feasibility of using the CCLA-based liposome to deliver siRNA against c-raf to cancer cells and tumor-bearing mice. The toxicity and transfection efficiency of the CCLA-based liposome with the reporter genes were also investigated.
Materials and methods

Preparation of CCLA-based cationic liposomes
Cholesterol and DOPE (dioleoylphosphatidylethanolamine) used as helper lipids were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). CCLA was synthesized in our laboratory according to previously described method. 18 Several CCLA-based liposomes were prepared from CCLA and helper lipids at different molar ratio using thin-film hydration method. 21 In brief, CCLA, DOPE or cholesterol were dissolved in chloroform in a round bottom flask. The solvent was removed under reduced pressure using a rotatory evaporator to form a lipid film, and further dried under vacuum overnight. The lipid film was hydrated with 10% sucrose in RNase-free water under nitrogen, at 25-401C. RNase-free water was obtained from Sigma (St Louis, MO). The bulk cationic liposomes were extruded through 0.2 mm pore size polycarbonate filter three times and 0.1 mm pore size polycarbonate filter five times. The extruded liposomes were sterilized by filtering through 0.22 mm sterile filter unit (Millipak s 20 positively charged). The prepared liposomes had a mean particle size of 110-120 nm. The size of the liposomes was characterized using a light scattering particle sizer (Nicomp Model 380, Santa Barbara, CA).
Cell culture
A549 (human lung cancer), PC-3 (human prostate cancer), SK-OV-3 (human ovarian cancer), MX-1 and MDA-MB-231 (human breast cancer) cells were obtained from the National Cancer Institute (Fredrick, MD) and maintained in RPMI 1640 medium containing 10% heatinactivated fetal bovine serum (HI-FBS). CHO (Chinese hamster ovary), BALB/3T3 (murine embryonic fibroblasts) and HepG 2 (human hepatocellular carcinoma) were purchased from American Type Culture Collection (Manassas, VA). CHO cells were maintained in Kaighn's modification of Ham's F12 medium (F12K) with 10% HI-FBS. BALB/3T3 cells were maintained in Dulbecco's modified Eagle's medium with 10% calf serum. HepG 2 cells were maintained in Eagle's minimum essential medium with 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids and 10% HI-FBS. All culture medium and reagents were purchased from Invitrogen Life Technologies (Carlsbad, CA).
In vitro transfection
At 1 day prior to transfection, CHO (25,000 cells/well), BALB/3T3 (25,000 cells/well), MX-1 (50,000 cells/well) and A549 (25,000 cells/well) were seeded in 96-well plates and HepG 2 (200,000 cells/well) in 24-well plates, and then cultured overnight in a 5% CO 2 incubator. The cells were then washed with phosphate-buffered saline to remove the residual serum before adding the transfection mixture.
The transfection efficiency of CCLA-based liposomes was determined using b-galactosidase (b-gal) reporter gene assay for CHO, BALB/3T3 and HepG 2 cells and luciferase reporter gene assay for MX-1 and A549 cells. The pSV-b-gal control vectors were purchased from Promega (Madison, WI) and the gWIZ luciferase vectors were purchased from Gene Therapy Systems (San Diego, CA). The total amount of DNA plasmids was 0.2 mg/well in 96-well plates and 1 mg/well in 24-well plates. The plasmids were diluted with OptiMEM I Reduced Serum Medium (Invitrogen, Carlsbad, CA) in cell culture tubes. Equal volume of OptiMEM I medium was used to dilute CCLA-based liposome. Appropriate amount of CCLAbased liposome was resuspended in OptiMEM I medium to obtain CCLA/DNA ( þ /À) charge ratio of 8:1 and diluted in series to 4:1, 2:1, 1:1 and 1:2 with OptiMEM I medium and incubated at room temperature for 5 minutes. DNA was then added drop by drop to CCLAbased liposome dilution and incubated at room temperature for additional 30 minutes. After incubation, the DNA/CCLA-based liposome complex was added to the cells and incubated further for 4-6 hours. After transfection, the residual DNA/CCLA-based liposome complex was washed off and the cells were replenished with regular culture medium and incubated up to 24 hours.
b-gal reporter gene assay was performed using b-gal Reporter Gene Assay System (Promega, Madison, WI) according to the manufacturer's protocol. The optical density of the sample was read at 414 nm using a plate reader (Thermo Electron, Franklin, MA). The amount of b-gal expression was calculated based on the exogenous bgal standard. The expression of luciferase was measured using Luciferase Assay System (Promega, Madison, WI). The assay reagent was mixed with 20 ml of cell lysate and the relative light unit was determined by a luminometer (Thermo Electron, Franklin, MA).
In vivo transfection
The transfection efficiency of CCLA-based liposome in male BALB/c mice was determined using luciferase reporter gene assay. The gWIZ luciferase vectors (50 mg/ mouse) were gently mixed to the surface of CCLA-based liposome. The DNA/CCLA-based liposome complex was injected to mice i.v. through tail vein within 8 hours of the CCLA-based liposome for nucleic acid delivery P-Y Chien et al preparation. BALB/c mice were obtained from Charles River Laboratories (Portage, MI). Equal quantity of DNA was delivered with In Vivo GeneSHUTTLEt, a DOTAP-based formulation (QBiogene, Carlsbad, CA) following the manufacturer's recommended protocol. The animals were killed 24 hours after the injection. The lung and heart tissues were quickly removed and frozen in an ethanol/dry ice bath. The tissues were then homogenized in Cell Culture Lysis Reagent (Promega, Madison, WI) using an Autogizer (Tomtec, Hamden, CT). The homogenate was centrifuged at 12,000 rpm (16,000 g) for 10 minutes at 41C and the supernatant was transferred to a separate tube. A 20 mL aliquot from the supernatant was used to measure the luciferase activity. The protein concentration of each tissue sample was determined using RC DC protein assay according to the manufacturer's protocol (Bio-Rad Laboratories, Hercules, CA).
In vivo toxicity study of CCLA-based liposome
The toxicity of CCLA-based liposome was determined in male BALB/c mice. The single-dose toxicity of the CCLAbased liposome was evaluated by injecting mice with 100 mg/kg of CCLA-based liposome via the tail vein. The DOTAP-based In Vivo GeneSHUTTLEt was included for comparative analysis. The multiple-dose toxicity was also examined by injecting mice with 50, 75 or 100 mg/kg of the CCLA-based liposome via the tail vein for 3 consecutive days. Three animals were used in each group. The mortality, body weight and clinical signs of toxicity were monitored daily for 14 days.
Delivery of siRNA using CCLA-based liposome
The therapeutic efficacy study of siRNA against c-raf was tested by transfecting c-raf siRNA to A549, PC-3, MDA-MB-231 and SK-OV-3 cancer cells with CCLA-based liposome. siRNA duplex was designed to target the specific sequence of human mRNA for c-raf gene (accession number X03484). The selected sequence was screened in BLAST search to verify that only c-raf mRNA was targeted. Synthetic siRNA duplex was custom synthesized at Dharmacon (Lafayette, CO) in the 2 0 -deprotected, desalted form. The sense and antisense sequence of the duplex were 5 0 -AUUCCUGCUCAAUG GAUUUdTdT-3 0 and 5 0 -AAAUCCAUUGAGCAGGA AUdTdT-3 0 , respectively. The mismatch double-stranded siRNA sequence (5 0 -AGCUUGCCAUCCAUGCUAUd TdT-3 0 and 5 0 -AUAGCAUGGAUGGCAAGCUdTdT-3 0 ) was also obtained from Dharmacon (Lafayette, CO). The mismatch sequence was also screened in BLAST search to verify that there was no homology with c-raf mRNA sequence. Approximately 10,000 cells/well were plated in a 96-well plate and transfected with 400 nM of c-raf siRNA or/and 10 mg/mL CCLA-based liposome for 6 hours. After transfection, the c-raf siRNA/CCLA-based liposome complex was washed off and the cells were replenished with fresh medium and incubated for 72 hours. The cytotoxicity of c-raf siRNA was determined using the sulforhodamine B (SRB) assay. 21, 22 The therapeutic efficacy of siRNA against c-raf was further tested against human breast tumor xenograft model in SCID mice. MDA-MB-231 cells (2 Â 10 6 cells in 0.1 ml HBSS) were injected subcutaneously to female C.B-17 SCID mice (4-5 weeks old from Harlan SpragueDawley, Indianapolis, IN). When tumors reached volume of 50-100 mm 3 , mice were randomized into four groups. Three groups were treated with free siRNA in RNaseand DNase-free water, mismatched c-raf siRNA/CCLAbased liposome or c-raf siRNA/CCLA-based liposome, respectively. The injection was conducted twice (b.i.d.) per day for 5 days through tail vein injection at 7.5 mg/kg/day of siRNA. Sucrose (10%, w/v) at equal volume of liposome complex was injected in the fourth group as control. The tumor size was measured twice per week with a caliper, and the tumor volume was calculated using the following formula: a Â (b/2) 2 Â p, where p ¼ 3.14, a and b are the tumor length and width, respectively. Mice were killed 15 days after the initial treatment when the tumors of the control group had reached the maximum volume (B400 mm 3 ). All data were expressed as mean7SEM. The comparison between groups was conducted with Student's t-test (two tailed, unpaired). It was considered to be statistically significant if P-value o.05.
Results and discussion
Transfection efficiency of the CCLA-based liposome with reporter genes It has been reported that different helper lipids 23 and the charge ratio of the positively charged lipid versus negatively charged DNA 24 can contribute to the variable transfection efficiency. To determine the optimal combination for the CCLA-based liposome transfection, two most commonly used helper lipids, cholesterol and DOPE, were formulated with CCLA at different molar ratio and screened for their transfection efficiency in vitro using b-gal reporter gene assay. The evaluation results showed that the formulation, composed of CCLA:DOPE at molar ratio of 1:2, had high transfection among the cell lines tested. Gene transfection has also been demonstrated with several monovalent cationic liposomes with molar ratio of cationic lipid to helper lipid close to 1:1. 1, 23, 25 CCLA has four hydrophobic chains and two positive charges, a structure resembling to two singly charged cationic lipids conjugated together. Therefore, the optimal molar ratio of CCLA to DOPE (1:2) is comparable to the ratio of 1:1 for other cationic and helper lipids. However, the optimal molar ratio of each cationic lipid to helper lipid can depend on various factors including the structure of the lipids and should be determined individually by measuring the biological activity.
A detailed study was conducted to determine the peak transfection efficiency of the CCLA-based liposome using b-gal and luciferase reporter genes assay in vitro. In CHO, BALB/3T3, A549 and MX-1 cells, the peak gene expression from reporter genes was obtained at 2:1 of CCLA/DNA ( þ /À) charge ratio, whereas in HepG 2 cells, the peak activity was at charge ratio of 1:1 (Fig 2) .
The in vivo transfection efficiency of CCLA-based liposome was further tested in male BALB/c mice by measuring the expression of luciferase 24 hours after the i.v. injection of CCLA/reporter gene complex. Several formulations, composed of CCLA and cholesterol or DOPE at different molar ratios, were screened. Interestingly, the molar ratio of CCLA:DOPE at 1:2, the same composition to the in vitro formulation, showed better transfection activity than CCLA with cholesterol. When different charge ratios of CCLA/DNA ( þ /À) were tested with 50 mg of luciferase reporter gene, the maximum expression of luciferase was observed at 5:1 ( þ /À) both in the lung and heart tissues (Fig 3a) . In contrast, no expression was observed in the mice treated with DNA-or CCLA-based liposome alone.
The transfection efficiency of CCLA-based liposomes was also compared with another commercially available cationic liposome (In Vivo GeneSHUTTLEt) in male BALB/c mice. The DOTAP-based In Vivo GeneSHUTTLEt is one of the very few commercially available liposome used for in vivo experiments. The luciferase reporter gene (50 mg/mouse) was delivered with either the optimal charge ratio ( þ /À 5:1) of CCLA-based liposomes or the In Vivo GeneSHUTTLEt using the manufacturer's recommended condition. Our results showed that the luciferase gene expression in lungs, if delivered by CCLA-based liposome, was approximately seven-fold higher than by In Vivo GeneSHUTTLEt (Fig 3b) . The calculated charge ratio of DOTAP to DNA was also approximately 5:1.
Similar to other cationic liposomes, CCLA also showed higher transfection efficiency in lungs after i.v. administration. Even though the mechanism of higher CCLA uptake in the lung is yet to be elucidated, several explanations have been provided for other cationic lipids. For instance, DOPE-containing cationic liposomes have been shown to bind to erythrocytes immediately after the i.v. injection, which embolize in the lung capillary with erythrocytes. 26 This results in the accumulation of cationic liposome-DNA complexes in the lung leading to the higher expression. Secondly, there is a preferable uptake of cationic liposome-DNA complexes by the pulmonary endothelial cells. After released from erythrocytes, the liposome-DNA complexes are then internalized by the endothelial cells. The uptake capability of cationic liposome by the capillary endothelial cells is shown to be highest in the lung, less in the muscle and heart. 27 In addition, the size of the liposomes has also been shown to play important role in the tissue distribution. Reduced distribution to the lung can be achieved by decreasing the size of the liposomes. 28 The size of the CCLA-based liposome (B110 nm) is within a similar range as shown for other cationic liposome. 23 Therefore, a similar pattern of CCLA-based liposome may have resulted in higher expression in the lung than in the heart. Based on the tissue distribution study conducted on a liposome formulation containing CCLA, cholesterol and dioleoylphosphatidylcholine (DOPC) to deliver antisense oligonucleotide, the highest level of the liposome was also detected in the lung, and the level of expression was in the order of lung4spleen4liver4kidney4heart (unpublished results).
Toxicity study of the CCLA-based liposome
Two studies were conducted to investigate the toxicity of the CCLA-based liposome in male BALB/c mice. Singledose toxicity study was performed by injecting 100 mg/kg of the CCLA-based liposome via tail vein injection. An equal dose of DOTAP-based In Vivo GeneSHUTTLEt was injected to a separate group of mice and used for comparison. No mortality was observed in CCLA liposome-treated group, whereas 66.6% mortality was recorded for the In Vivo GeneSHUTTLEt-treated group (Table 1 ). In the multiple-dose toxicity study, mice were injected with 50, 75 or 100 mg/kg of CCLA-based liposome for 3 consecutive days. No mortality was seen in the groups injected with 50 and 75 mg/kg/day, whereas 33.3% mice died 3 days after receiving 100 mg/kg/day of CCLA-based liposome (Table 1 ). There was no significant body weight loss in 50 and 75 mg/kg treated groups and only up to 10.1% weight loss occurred in mice treated with 100 mg/kg/day of CCLA-based liposome. The surviving animals completely recovered 10 days after the initial treatment. Our results indicated that the toxicity of CCLA-based liposome was significantly lower than In Vivo GeneSHUTTLEt. Even though the detail mechanistic toxicity profile of the CCLA-based liposome is yet to be determined, it has been reported that transfection can be enhanced with reduced toxicity by using multivalent charged lipids. Male BALB/ c mice were injected intravenously with 50 mg/mouse of luciferase reporter gene in the presence of CCLA-based liposome to obtain charge ratio ( þ /À) from 4:1 to 6:1. DNA alone or CCLA-based liposome dose used for 6:1 ( þ /À) charge ratio were injected to a separate group of animals and used as control. The CCLA-based liposome was composed of CCLA and DOPE at 1:2 molar ratio. The lung and heart tissues were removed 24 hours after the injection and the expression of luciferase was used to determine the optimal charge ratio of CCLA to reporter gene. The data were expressed as mean7SEM of each group. (b) The comparative transfection study of CCLA-and DOTAP-based liposomes. The optimal transfection efficiency of CCLA-based liposome ( þ /À charge ratio 5:1) was compared to the DOTAP-based In Vivo GeneSHUTTLEt, using the manufacturer's recommended protocol. The final charge ratio ( þ /À) of In Vivo GeneSHUTTLEt was approximately 5:1. Male BALB/c mice were injected with CCLA-based liposome once (single dose) or once a day for 3 days (multiple dose) through tail vein injection. Three animals were used in each group. The composition of CCLA-based liposome is CCLA: DOPE at molar ratio of 1:2. The DOTAP-based In vivo GeneSHUTTLEt was included as comparison in the singledose study. The body weight loss and the mortality were monitored after the injection.
Therapeutic application of CCLA-based liposome
It has been shown that siRNAs are powerful agents to inhibit gene expression through specific RNA interference. 19 However, due to the rapid degradation of siRNA, delivery in vivo remains a challenge for a successful therapeutic usage of siRNA. As a member of the serine/ threonine protein kinase family, c-raf has been shown to play a key role in mitogen-activated protein kinase signaling cascade 30 and involve in tumor progression. 31, 32 Inhibiting the expression of c-raf with antisense oligonucleotides has been shown to suppress the tumor growth in vitro and in xenograft tumor models. 32, 33 To test siRNAmediated suppression of c-raf expression using CCLAbased liposome, siRNA was prepared to target c-raf in cultured cancer cells and in mice bearing tumor. A549, PC-3, MDA-MB-231 and SK-OV-3 cells were transfected with siRNA alone, or CCLA-based liposome alone, or the combination of both. The cytotoxicity was measured 72 hours after the transfection using SRB assay. The results showed that 400 nM of siRNA, delivered by CCLA-based liposome, induced 54, 62, 33 and 34% cytotoxicity in A549, PC-3, MDA-MB-231 and SK-OV-3 cells, respectively, as compared to the control cells. No apparent cytotoxicity was seen in cells treated with free siRNA or liposome alone (Fig 4) .
The in vivo therapeutic efficacy of c-raf siRNA was investigated in SCID mice bearing human breast cancer (MDA-MB-231) xenografts. The treatment of c-raf siRNA/CCLA-based liposome complex exhibited 73% tumor growth inhibition as compared to free c-raf siRNA group 8 days after the initial treatment (Fig 5) . The difference was found to be statistically significant (P o.05 in t-test). In contrast, 10% sucrose, free c-raf siRNA or mismatch siRNA delivered by CCLA-based liposome had no significant effect on the tumor growth.
In conclusion, a novel CCLA-based liposome has been developed based on CCLA. The CCLA-based liposome, composed of CCLA:DOPE at molar ratio of 1:2, was shown to transfect reporter genes and siRNA efficiently both in vitro and in vivo. In addition, the CCLA-based liposome had lower toxicity than the DOTAP-based In Vivo GeneSHUTTLEt. All the results suggested that the CCLA-based liposome can be used as a nucleic acid delivery reagent for both in vitro and in vivo studies.
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